Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2 WT and SHP2F285S by molecular dynamics study.

Journal of molecular graphics & modelling - 1 Mar 2021

Zhou Liang, Feng Yong, Ma Yang-Chun, Zhang Zhao, Wu Jing-Wei, Du Shan, Li Wei-Ya, Lu Xin-Hua, Ma Ying, Wang Run-Ling

Abstract excerpt

Abnormal activation of Ras/MAPK signaling pathway could trigger excessive cell division. Src-homology 2 (SH2) domain-containing protein tyrosine phosphatase (SHP2) could promote Ras/MAPK activation by integrating growth factor signals. Thus, SHP2 inhibitors had become a hot topic in the treatment of cancer. SHP2F285S, mutation in SHP2, was detected in leukemia variants. The compound 2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Molecular Conformation
Share to Molecular Docking Simulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Dynamics Simulation

Share to Mutation

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Source

Identifiers

PMID: 33338846
DOI: 10.1016/j.jmgm.2020.107807

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2 WT and SHP2F285S by molecular dynamics study.PMID 33338846Read ↗

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.Semantic proximity Read ↗

Design, synthesis, biological evaluation, common feature pharmacophore model and molecular dynamics simulation studies of ethyl 4-(phenoxymethyl)-2-phenylthiazole-5-carboxylate as Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.Semantic proximity Read ↗

Strategies to overcome drug resistance using SHP2 inhibitorsSemantic proximity Read ↗

Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.Semantic proximity Read ↗

Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy.Semantic proximity Read ↗

Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.Semantic proximity Read ↗

Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020).Semantic proximity Read ↗

The Landscape of Protein Tyrosine Phosphatase (Shp2) and CancerSemantic proximity Read ↗

Targeting SHP2 phosphatase in hematological malignancies.Semantic proximity Read ↗

Inhibition of SHP2 as an approach to block RAS-driven cancers.Semantic proximity Read ↗

SHP2 Inhibition Benefits Epidermal Growth Factor Receptor-mutated Non-Small Cell Lung Cancer Therapy.Semantic proximity Read ↗

An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphataseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.